Middle East and Africa Autoinjectors Market

Market Overview

The Middle East and Africa Autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 10.3% during the forecast period (2022-2030).

Highlights

• Anaphylaxis dominates the market by therapy.
• Disposable dominates the market by type.
• Homecare dominates the market by end-user.

Autoinjectors are pre-filled syringes with needles held in place by a spring. When a sliding motion is used to inject the device into the body, it turns on and gives a measured dose of medicine. Autoinjectors are used to give yourself epinephrine to avoid anaphylaxis or to quickly relieve pain from a migraine, as well as for medical and emergency treatments. Autoinjectors have several benefits, such as making people less afraid of needles, lowering the chance that a needle will get stuck, keeping the dose quality consistent, and helping people be more successful.

Market Dynamics

Middle East and Africa Autoinjectors Market Drivers

Pressing Need for Patients' Convenience

Saudi Arabia follows the trend of using autoinjectors to improve patient compliance. Autoinjectors let patients self-administer drugs safely and accurately. This convenience helps patients stick to treatment plans and overcome hurdles to healthcare, especially in remote or underdeveloped locations. Autoinjectors are also supported by MEA healthcare infrastructure and patient-centric care programs. Governments and healthcare institutions understand the need for easy and patient-friendly chronic illness management options.

Middle East and Africa Autoinjectors Market Restraints

Limited Health Infrastructure

Limited healthcare infrastructure in rural sub-Saharan Africa hinders autoinjector usage. These places lack well-equipped healthcare facilities, trained healthcare workers, and adequate distribution networks, making autoinjectors difficult to access and use. Sub-Saharan Africa lacks healthcare infrastructure, according to the WHO. Many countries in this region lack healthcare facilities, especially in rural areas. In 2017, the WHO estimated that sub-Saharan Africa had 2.6 healthcare workers per 1,000 people, compared to 10.3 globally.

Middle East and Africa Autoinjectors Market Opportunities

Growing Demand for Biological Therapies

Biologic therapy for rheumatoid arthritis and psoriasis has increased in the region. Autoinjectors are preferable for subcutaneous injections of biological medicines. Autoinjectors improve medication adherence and treatment outcomes due to their convenience. Biologic therapy is growing in Saudi Arabia and the UAE, where healthcare infrastructure is built. Biologic medications for rheumatoid arthritis and psoriasis have increased in the UAE. Thus, autoinjectors, a convenient and efficient drug delivery technology, are in demand. This shows that autoinjector producers can profit from the region's increased need for biological medicines.

Regional Analysis

The Middle East and Africa Autoinjectors market is analyzed by country in the UAE, South Africa, Saudi Arabia, and the Rest of the Middle East and Africa. The rest of the Middle East and Africa dominated the market and is expected to grow at a CAGR of 9.9% during the forecast period.

The Middle East and Africa had the lowest Autoinjectors market share due to weak healthcare infrastructure, notably in Africa. Demographics drive Middle East and Africa autoinjector sales. Population dynamics are increasing and aging. For instance, Africa is expected to become the 2nd most populous continent in ten years, and the Middle East's population growth rate has been around 2% for a decade. The region's average lifespan is 73 years, comparable to many wealthy nations. Lifestyle changes have increased non-contagious chronic diseases and disorders, which will increase autoinjector demand.

This region's rising rates of anaphylaxis and food allergies drive the worldwide autoinjectors market. Autoinjectors will be in great demand due to the increased prevalence of diabetes, asthma, cardiovascular diseases, arthritis, etc. Adrenaline and epinephrine autoinjectors are in high demand due to rising anaphylaxis rates. The tendency toward self-treatment boosts autoinjector growth. Infectious illnesses and Hospital-Acquired Infections (HAIs) are expected to drive market growth and needle stick injury prevention using autoinjectors.

However, difficult economic conditions, a shortage of competent healthcare professionals and nurses with autoinjector expertise, and an underdeveloped healthcare infrastructure hinder regional market growth. According to an NCBI study, Africa lacks epinephrine autoinjectors for outpatients at risk of anaphylaxis.

However, significant market players can build businesses and launch new, cost-effective autoinjector devices in this region. Autoinjector manufacturing improvements and medical device and pharma sector growth are projected to drive the business. Demand is expected to rise due to the Middle East and Africa's aging population. Government activities will support regional market growth to raise awareness of the benefits of self-injection. Foreign nations build manufacturing operations in the Middle East and Africa due to cheap labor and lax regulations. This market's main players can expand into the Middle East and Africa and launch affordable autoinjectors to boost demand.

Segmental Analysis

The Middle East and Africa Autoinjectors market is segmented based on therapy, type, end-user, and country.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 9.5% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 9.7% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 10.9% during the forecast period.

Recent Developments

• May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.